CN101410402A - 丁丙诺啡衍生物及其应用 - Google Patents

丁丙诺啡衍生物及其应用 Download PDF

Info

Publication number
CN101410402A
CN101410402A CNA2007800108118A CN200780010811A CN101410402A CN 101410402 A CN101410402 A CN 101410402A CN A2007800108118 A CNA2007800108118 A CN A2007800108118A CN 200780010811 A CN200780010811 A CN 200780010811A CN 101410402 A CN101410402 A CN 101410402A
Authority
CN
China
Prior art keywords
buprenorphine
compound
salt
replaces
compounds
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CNA2007800108118A
Other languages
English (en)
Chinese (zh)
Inventor
克利斯托弗·波恩·夏普利奥
约翰·威廉·刘易斯
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Reckitt Benckiser Healthcare UK Ltd
Original Assignee
Reckitt Benckiser Healthcare UK Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Reckitt Benckiser Healthcare UK Ltd filed Critical Reckitt Benckiser Healthcare UK Ltd
Publication of CN101410402A publication Critical patent/CN101410402A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D489/00—Heterocyclic compounds containing 4aH-8, 9 c- Iminoethano-phenanthro [4, 5-b, c, d] furan ring systems, e.g. derivatives of [4, 5-epoxy]-morphinan of the formula:
    • C07D489/09—Heterocyclic compounds containing 4aH-8, 9 c- Iminoethano-phenanthro [4, 5-b, c, d] furan ring systems, e.g. derivatives of [4, 5-epoxy]-morphinan of the formula: containing 4aH-8, 9 c-Iminoethano- phenanthro [4, 5-b, c, d] furan ring systems condensed with carbocyclic rings or ring systems
    • C07D489/10—Heterocyclic compounds containing 4aH-8, 9 c- Iminoethano-phenanthro [4, 5-b, c, d] furan ring systems, e.g. derivatives of [4, 5-epoxy]-morphinan of the formula: containing 4aH-8, 9 c-Iminoethano- phenanthro [4, 5-b, c, d] furan ring systems condensed with carbocyclic rings or ring systems with a bridge between positions 6 and 14
    • C07D489/12—Heterocyclic compounds containing 4aH-8, 9 c- Iminoethano-phenanthro [4, 5-b, c, d] furan ring systems, e.g. derivatives of [4, 5-epoxy]-morphinan of the formula: containing 4aH-8, 9 c-Iminoethano- phenanthro [4, 5-b, c, d] furan ring systems condensed with carbocyclic rings or ring systems with a bridge between positions 6 and 14 the bridge containing only two carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/485—Morphinan derivatives, e.g. morphine, codeine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36—Opioid-abuse

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Neurology (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurosurgery (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Addiction (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Emergency Medicine (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
CNA2007800108118A 2006-03-28 2007-03-27 丁丙诺啡衍生物及其应用 Pending CN101410402A (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB0606124.6 2006-03-28
GBGB0606124.6A GB0606124D0 (en) 2006-03-28 2006-03-28 Buprenorphine derivatives and uses thereof

Related Child Applications (1)

Application Number Title Priority Date Filing Date
CN201410318622.9A Division CN104151320A (zh) 2006-03-28 2007-03-27 丁丙诺啡衍生物及其应用

Publications (1)

Publication Number Publication Date
CN101410402A true CN101410402A (zh) 2009-04-15

Family

ID=36384277

Family Applications (2)

Application Number Title Priority Date Filing Date
CNA2007800108118A Pending CN101410402A (zh) 2006-03-28 2007-03-27 丁丙诺啡衍生物及其应用
CN201410318622.9A Pending CN104151320A (zh) 2006-03-28 2007-03-27 丁丙诺啡衍生物及其应用

Family Applications After (1)

Application Number Title Priority Date Filing Date
CN201410318622.9A Pending CN104151320A (zh) 2006-03-28 2007-03-27 丁丙诺啡衍生物及其应用

Country Status (21)

Country Link
US (1) US7964610B2 (https=)
EP (1) EP2001891B1 (https=)
JP (1) JP5167446B2 (https=)
KR (1) KR101430626B1 (https=)
CN (2) CN101410402A (https=)
AU (1) AU2007231133B2 (https=)
BR (1) BRPI0709157A8 (https=)
CA (1) CA2647417C (https=)
DK (1) DK2001891T3 (https=)
ES (1) ES2432169T3 (https=)
GB (1) GB0606124D0 (https=)
IL (1) IL193917A (https=)
MX (1) MX2008011984A (https=)
MY (1) MY151025A (https=)
NZ (1) NZ570997A (https=)
PL (1) PL2001891T3 (https=)
PT (1) PT2001891E (https=)
RU (1) RU2435773C2 (https=)
TW (1) TWI501969B (https=)
WO (1) WO2007110636A1 (https=)
ZA (1) ZA200807614B (https=)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN108289887A (zh) * 2015-10-26 2018-07-17 奥佛麦德公司 丁丙诺啡的乙二醇醚
CN116283893A (zh) * 2023-03-22 2023-06-23 阜阳欣奕华制药科技有限公司 硫代羟基乙酸酐的制备方法
TWI838372B (zh) * 2018-05-11 2024-04-11 昱展新藥生技股份有限公司 丁基原啡因衍生物之長效注射劑型及結晶型

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2549115T3 (es) 2006-09-22 2015-10-23 Zynerba Pharmaceuticals, Inc. Profármacos de buprenorfina administrables por vía transdérmica y composiciones resistentes al consumo excesivo de los mismos
SI2307420T1 (sl) * 2008-04-24 2012-05-31 Janssen Pharmaceutica Nv Predzdravila nalmefen di estra
FR2975912B1 (fr) 2011-05-30 2013-06-14 Flamel Tech Sa Composition a liberation controlee de buprenorphine
JP2019507783A (ja) 2016-03-09 2019-03-22 エムダブリュ エンキャップ リミテッド 乱用防止医薬製剤
TWI743193B (zh) * 2016-09-13 2021-10-21 昱展新藥生技股份有限公司 丁基原啡因緩釋製劑
WO2019064026A1 (en) 2017-09-29 2019-04-04 Orexo Ab NEW PHARMACEUTICAL COMPOSITIONS
GB201904767D0 (en) 2019-04-04 2019-05-22 Orexo Ab New pharmaceutical compositions
WO2023102489A1 (en) * 2021-12-03 2023-06-08 Board Of Regents Of The University Of Nebraska Compounds, nanoparticles, and pharmaceutical compositions for the treatment of drug addiction

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4668685A (en) * 1984-07-05 1987-05-26 E.I. Du Pont De Nemours And Company Substituted benzoate ester prodrug derivatives of 3-hydroxymorphinans, which are analgesics or narcotic antagonists
GB8728294D0 (en) * 1987-12-03 1988-01-06 Reckitt & Colmann Prod Ltd Treatment compositions
US5985880A (en) * 1996-06-05 1999-11-16 Delta Pharmaceuticals Compositions and methods for reducing respiratory depression and attendant side effects of mu opioid compounds
US5512593A (en) * 1993-03-02 1996-04-30 John S. Nagle Composition and method of treating depression using natoxone or naltrexone in combination with a serotonin reuptake inhibitor
US5750534A (en) * 1994-03-16 1998-05-12 National Science Council Nalbuphine esters having long acting analgesic action and method of use
US6004969A (en) * 1996-04-15 1999-12-21 National Science Council Transdermal delivery of buprenorphine preparations
KR100204659B1 (ko) * 1996-05-28 1999-06-15 강재헌 신규한 부프레노핀계 진통제용 화합물
US6225321B1 (en) * 1997-06-05 2001-05-01 Oliver Yoa-Pu Hu Long analgesic acting nalbuphine polyester derivative and method of use
AU756852B2 (en) 1998-11-13 2003-01-23 Jagotec Ag Dry powder for inhalation
US6716449B2 (en) * 2000-02-08 2004-04-06 Euro-Celtique S.A. Controlled-release compositions containing opioid agonist and antagonist
EP2092936B1 (en) * 2000-02-08 2013-03-20 Euro-Celtique S.A. Tamper-resistant oral opioid agonist formulations
AU2002337686B2 (en) * 2001-09-26 2008-05-15 Penwest Pharmaceuticals Company Opioid formulations having reduced potential for abuse
US20040033253A1 (en) * 2002-02-19 2004-02-19 Ihor Shevchuk Acyl opioid antagonists
US7666876B2 (en) * 2002-03-19 2010-02-23 Vernalis (R&D) Limited Buprenorphine formulations for intranasal delivery
US7776314B2 (en) * 2002-06-17 2010-08-17 Grunenthal Gmbh Abuse-proofed dosage system
DE60329515D1 (de) * 2002-10-25 2009-11-12 Euro Celtique Sa Analoga und prodrugs von buprenorphin
US20050186139A1 (en) * 2002-10-25 2005-08-25 Gruenenthal Gmbh Abuse-proofed dosage form
DE10250084A1 (de) * 2002-10-25 2004-05-06 Grünenthal GmbH Gegen Missbrauch gesicherte Darreichungsform
US20050191244A1 (en) * 2002-10-25 2005-09-01 Gruenenthal Gmbh Abuse-resistant pharmaceutical dosage form
DE10250087A1 (de) 2002-10-25 2004-05-06 Grünenthal GmbH Gegen Missbrauch gesicherte Darreichungsform
RU2215741C1 (ru) * 2002-11-05 2003-11-10 Открытое Акционерное Общество "Международная Научно-Технологическая Корпорация" Сложные эфиры n-замещенных 14-гидроксиморфинанов и способ их получения
CN1263760C (zh) * 2002-11-12 2006-07-12 财团法人奇美医院 新颖的丁丙诺啡酯衍生物及其制备方法，以及长效作用镇痛药学组合物
DE60224288T2 (de) * 2002-11-25 2009-04-16 Chi Mei Foundation Medical Center Buprenorphinesterderivate, Verfahren zu ihrer Herstellung, und langwirksame analgetische Arzneimittel
JP2004175706A (ja) * 2002-11-26 2004-06-24 Chi Mei Foundation Medical Center 新規なブプレノルフィンのエステル誘導体及びそれらの調製方法、及び長時間効力持続性鎮痛薬剤組成物
TW200500067A (en) * 2003-01-21 2005-01-01 Control Delivery Sys Inc Salts of codrugs and uses related thereto
US7501113B2 (en) * 2003-02-04 2009-03-10 Philip Morris Usa Inc. Aerosol formulations and aerosol delivery of buprenorphine
US7195882B2 (en) * 2003-06-03 2007-03-27 Roche Diagnostics Operations, Inc. Monoclonal antibodies specific for buprenorphine and metabolites thereof
US7759358B2 (en) * 2003-07-23 2010-07-20 Crooks Peter A Oral bioavailable prodrugs
US7589233B2 (en) * 2003-07-29 2009-09-15 Signature R&D Holdings, Llc L-Threonine derivatives of high therapeutic index
US7220842B2 (en) * 2004-04-05 2007-05-22 Dade Behring Inc. Immunoassays for buprenorphine and norbuprenorphine

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN108289887A (zh) * 2015-10-26 2018-07-17 奥佛麦德公司 丁丙诺啡的乙二醇醚
TWI838372B (zh) * 2018-05-11 2024-04-11 昱展新藥生技股份有限公司 丁基原啡因衍生物之長效注射劑型及結晶型
CN116283893A (zh) * 2023-03-22 2023-06-23 阜阳欣奕华制药科技有限公司 硫代羟基乙酸酐的制备方法
CN116283893B (zh) * 2023-03-22 2024-04-26 阜阳欣奕华制药科技有限公司 硫代羟基乙酸酐的制备方法

Also Published As

Publication number Publication date
DK2001891T3 (da) 2013-11-04
CN104151320A (zh) 2014-11-19
MX2008011984A (es) 2008-10-03
KR20080105124A (ko) 2008-12-03
RU2435773C2 (ru) 2011-12-10
ES2432169T3 (es) 2013-12-02
AU2007231133B2 (en) 2011-09-01
US7964610B2 (en) 2011-06-21
KR101430626B1 (ko) 2014-08-18
RU2008142527A (ru) 2010-05-10
MY151025A (en) 2014-03-31
AU2007231133A8 (en) 2011-08-25
ZA200807614B (en) 2009-10-28
BRPI0709157A8 (pt) 2018-04-24
WO2007110636A1 (en) 2007-10-04
TWI501969B (zh) 2015-10-01
BRPI0709157A2 (pt) 2011-06-28
PL2001891T3 (pl) 2014-03-31
CA2647417C (en) 2014-09-23
CA2647417A1 (en) 2007-10-04
PT2001891E (pt) 2013-10-30
NZ570997A (en) 2011-08-26
AU2007231133A2 (en) 2008-10-16
EP2001891B1 (en) 2013-07-24
JP2009531406A (ja) 2009-09-03
GB0606124D0 (en) 2006-05-03
US20100234412A1 (en) 2010-09-16
EP2001891A1 (en) 2008-12-17
JP5167446B2 (ja) 2013-03-21
TW200806672A (en) 2008-02-01
AU2007231133A1 (en) 2007-10-04
IL193917A (en) 2014-12-31

Similar Documents

Publication Publication Date Title
CN101410402A (zh) 丁丙诺啡衍生物及其应用
JPH0699435B2 (ja) 経口投与のための麻薬拮抗剤
FI67686B (fi) Foerfarande foer framstaellning av nya terapeutiskt anvaendbara fenetanolaminderivat
JPH0776174B2 (ja) 医薬組成物および処置法
WO2008128431A1 (fr) Dérivés de l-stépholidine (l-spd), leurs procédés de préparation et d'utilisation
US6150524A (en) Morphine derivatives with analgesic activity
JP2000505448A (ja) カンプトテシン誘導体及び抗腫瘍剤としてのその利用
US4315920A (en) Adenosine deaminase inhibitors
CA2110529A1 (en) Diazepine derivatives
US6770654B2 (en) Indole derivatives and use thereof in medicines
HK1130259A (en) Buprenorphine derivatives and uses thereof
EP1118324A1 (en) Analgesic agent comprising a cyclobutanedicarboxylic acid derivative
JPH0341458B2 (https=)
JPH1160484A (ja) Ｔｎｆ産生阻害剤
US20200325157A1 (en) Novel Thiophene Compounds for Long-Acting Injectable Compositions and Related Methods
JPH03264585A (ja) イミダゾキノロン誘導体
SK7162002A3 (en) 2-arylquinoline derivatives, preparation and therapeutic use thereof
JPH09227559A (ja) スピロ置換三環性複素環式化合物
HK1011359B (en) Tropyl 7-azaindol-3-ylcarboxyamides as antitussive agent

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 1130259

Country of ref document: HK

ASS Succession or assignment of patent right

Owner name: RB MEDICAL LTD.

Free format text: FORMER OWNER: RECKITT BENCKISER HEALTHCARE (UK) LIMITED

Effective date: 20121218

C41 Transfer of patent application or patent right or utility model
TA01 Transfer of patent application right

Effective date of registration: 20121218

Address after: Burke County, England

Applicant after: RECKITT BENCKISER HEALTHCARE (UK) LIMITED

Address before: Burke County, England

Applicant before: Reckitt & Benksl Health-Care (England) Ltd.

C12 Rejection of a patent application after its publication
RJ01 Rejection of invention patent application after publication

Application publication date: 20090415

REG Reference to a national code

Ref country code: HK

Ref legal event code: WD

Ref document number: 1130259

Country of ref document: HK